Price
No data yet.
Social Signal Score
Revenue
$73.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Yehiel Tal
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 39
- Beta
- 0.68
- Country
- IL
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -23.05
Financials
Revenue
$73.0K+197.9%Net Income
$-3.10MEBITDA
$-2.89MFree Cash Flow
$-3.06MEPS (diluted)
$-0.23Shares Outstanding (diluted)
13.75M+607.3%Operating Expenses
$2.87MCash & Debt
$4.26MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.37M | $-11.49M | $-0.94 |
| 2024 | $515.0K | $-16.61M | $-1.45 |
| 2023 | $10.96M | $-7.02M | $-0.62 |
| 2022 | $299.0K | $-16.93M | $-1.52 |
| 2021 | $15.64M | $237.0K | $0.04 |
| 2020 | $6.14M | $-5.77M | $-0.84 |
| 2019 | $2.32M | $-11.16M | $-2.95 |
| 2018 | $4.79M | $-6.25M | $-1.43 |
| 2017 | $479.9K | $-5.80M | $-2.27 |
| 2016 | $75.9K | $-7.27M | $-3.60 |
| 2015 | $0.00 | $-4.80M | $-2.83 |
| 2014 | $0.00 | $-3.64M | $-2.08 |
| 2013 | $0.00 | $-4.56M | $-4.56 |
| 2012 | $0.00 | $-4.46M | $-5.37 |
Valuation
CLGNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsprnewswire.com·5h ago·Neutral
COLLPLANT ANNOUNCES REVERSE SHARE SPLIT REHOVOT, Israel, Sept. 1, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd.
View source ↗
Earnings
Wed, Dec 2(in 3 months)
Consensus estimate $-0.05 per share
Typical surprise +8.4% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, May 29$-0.23 vs $-0.24beat
- Thu, Mar 26$-0.26 vs $-0.30beat
- Wed, Nov 26$-0.27 vs $0.38miss
- Wed, Aug 20$-0.28 vs $-0.10miss
- Wed, May 28$-0.13 vs $-0.37beat
- Wed, Mar 26$-0.34 vs $-0.42beat
Estimates and results for CLGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CLGN officers and directors.
No open-market trades in the recent filings. All 34 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
34 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.